Abstract
Importance Most studies of ADPKD genetics have used select cohorts, focusing on PKD1 and PKD2 and more recently several other cystic genes. However, the population prevalence of ADPKD and the contribution of each cystic gene to ADPKD are not well understood.
Objective Determine the prevalence of ADPKD, contribution of PKD1, PKD2, and other cystic genes to ADPKD in a large, unselected cohort.
Design, Setting, and Participants We determined the prevalence of ADPKD In an unselected health system-based cohort of 173,954 subjects with the existing exome sequencing and extensive electronic health records, including abdominal imaging. The presence of genetic variants in PKD1, PKD2, and eleven other cystic genes was evaluated. Rare genetic variants were identified in patients with chart review confirmed diagnosis of ADPKD.
Main Outcomes Diagnosis of ADPKD and presences of rare (AF<0.0001) missense, protein-truncating variants (PTVs), or copy number variants deletions (CNV) in PKD1, PKD2, or PTVs and CNVs in the following 11 genes: ALG8, ALG9, DNAJB11, GANAB, HNF1B, IFT140, LRP5, PKHD1, PRKCSH, SEC61B, and SEC63.
Results Among 173,954 patients, there were 235 patients with chart review confirmed ADPKD (0.135%). Among patients with PTV or CNV in PKD1, 66/70 (94.2%) had ADPKD and 43/44 (97.7%) of patients with PTV or CNV in PKD2 had ADPKD. In contrast, only 24/77 (31.2%) patients with a PKD1 missense variant previously classified as “likely pathogenic” had ADPKD. A rare variant was identified in a cystic gene in 180/235 (76.6%) of ADPKD patients, with the most common genes implicated PKD1 (127) and PKD2 (34) and then IFT140 (7), PKHD1 (3), GANAB (4), HNF1B (2), ALG8 (1), ALG9 (1), IFT140+PKHD1 (1). The yield for a genetic determinant of ADPKD was 91.3% among those with a family history compared to 50.6% among those without a family history (p<0.0001). We report several previously unreported variants where pedigree data suggest pathogenicity. Atypical cystic genes ALG8, ALG9, GANAB, HNF1B, IFT140, and SEC63 were associated with having any kidney or liver cystic ICD code, but not diagnosed ADPKD.
Conclusions Exome sequencing established the molecular diagnosis for the vast majority of patients with ADPKD, revealed a wider range of ADPKD with atypical cystic genes. Additional population-based research cohorts are needed to carefully curate missense PKD1 variants and variants in atypical cystic genes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIDDK106515 to A.C and GM111913 to T.M. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Geisinger gave ethical approved this study. Informed consent was waived as participants were previously consented in the MyCode Community Health Initiative.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-first author
The text has been edited. Figures have been revised/combined. New Supplemental data has been added. Additional Author added.
Data Availability
The data supporting the findings of this study are available within the article and its Supplementary Data files. Additional information for reproducing the results described in the article is available upon reasonable request and subject to a data use agreement.
